List of Excipients in Branded Drug ABILIFY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	ABILIFY	aripiprazole	16590-323	ALUMINUM OXIDE
STAT RX USA LLC	ABILIFY	aripiprazole	16590-323	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	ABILIFY	aripiprazole	16590-323	FD&C BLUE NO. 2

Last updated: August 19, 2026

ABILIFY’s largest excipient opportunities are in differentiated oral disintegrating tablets, pediatric oral liquids, long-acting injectable suspensions, and generic products that improve manufacturability without changing aripiprazole exposure. The active ingredient is a poorly water-soluble, high-value antipsychotic with extensive generic competition in oral forms. Commercial protection has shifted from the original oral product to formulation, delivery-system, device, and long-acting injectable strategies.

ABILIFY Excipient Strategy and Commercial Opportunities for Aripiprazole

What is ABILIFY and which dosage forms are commercially relevant?

ABILIFY is the branded product for aripiprazole, an atypical antipsychotic marketed by Otsuka Pharmaceutical and commercialized in the United States with Bristol Myers Squibb during the original franchise. Aripiprazole is approved for schizophrenia, bipolar I disorder, major depressive disorder adjunctive therapy, Tourette's disorder, and irritability associated with autistic disorder, depending on dosage form and age group.[1-4]

The principal U.S. dosage forms are:

Product	Dosage form	Active ingredient	Primary commercial role
Abilify	Immediate-release tablet	Aripiprazole	Original oral product; generic competition
Abilify Discmelt	Orally disintegrating tablet	Aripiprazole	Swallowing and adherence differentiation
Abilify oral solution	Oral liquid	Aripiprazole	Pediatric and swallowing-limited patients
Abilify Maintena	Extended-release intramuscular suspension	Aripiprazole monohydrate	Monthly long-acting injectable
Abilify Asimtufii	Extended-release intramuscular suspension	Aripiprazole monohydrate	Two-month long-acting injectable

The oral products are mature generic markets. Maintena and Asimtufii have the stronger commercial position because their value depends on depot technology, reconstitution, injection administration, clinical workflow, and adherence rather than only on the active ingredient.

What excipients are used in ABILIFY tablets?

The immediate-release tablet uses a conventional solid-dose excipient platform. The U.S. prescribing information identifies corn starch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate as inactive ingredients.[1]

ABILIFY tablet excipient functions

Excipient	Likely formulation function
Corn starch	Disintegrant and filler
Hydroxypropyl cellulose	Binder
Lactose monohydrate	Diluent and filler
Magnesium stearate	Lubricant
Microcrystalline cellulose	Diluent and compression aid
Povidone	Binder
Sodium lauryl sulfate	Wetting agent and dissolution aid

This composition reflects a standard direct-compression or wet-granulation approach. The key development issue is aripiprazole’s low aqueous solubility. Sodium lauryl sulfate and the hydrophilic polymer system help wetting and dispersion, but the formulation does not create a high-solubility product. Generic manufacturers therefore have room to optimize granulation, particle size, lubricant level, dissolution robustness, and tablet hardness without necessarily creating a new intellectual-property position.

Commercial opportunities include:

• lower-cost high-speed tablet manufacturing;
• reduced tablet weight;
• lower lubricant sensitivity;
• improved dissolution across pH conditions;
• lactose-free or lower-lactose alternatives;
• reduced sodium lauryl sulfate for patients sensitive to surfactants;
• packaging improvements for moisture protection;
• pediatric strengths and mini-tablets.

What excipients are used in ABILIFY Discmelt orally disintegrating tablets?

Abilify Discmelt uses mannitol, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, potassium polacrilin, magnesium stearate, silicon dioxide, sucralose, and tartaric acid, according to the product label.[2]

Why does the Discmelt excipient system matter?

The formulation is designed to disintegrate rapidly in the mouth while maintaining acceptable taste and mechanical integrity. Its excipient architecture combines:

• mannitol for a cooling mouthfeel and rapid dissolution;
• crospovidone and potassium polacrilin for rapid wicking and swelling;
• hydroxypropyl cellulose for binding;
• silicon dioxide for flow and moisture control;
• sucralose for taste correction;
• tartaric acid for flavor balance and pH adjustment;
• magnesium stearate for lubrication.

The formulation is commercially attractive because aripiprazole has a bitter taste and an ODT cannot rely on swallowing to avoid oral exposure. Taste masking is therefore a core product attribute, not a secondary excipient decision.

What ODT opportunities exist for generic aripiprazole?

Generic developers can pursue several strategies:

1. Ion-exchange resin complexes using resins such as polacrilin or other pharmaceutical-grade cationic materials.
2. Polymer or lipid taste-masking coatings.
3. Co-processed mannitol-based excipient systems.
4. Spray-dried aripiprazole dispersions.
5. Lower-friability ODTs that tolerate commercial packaging and transport.
6. Smaller tablets for pediatric or geriatric patients.
7. ODTs with reduced sugar content or alternative sweeteners.
8. Orally dispersible granules or stick-pack presentations.

The primary regulatory constraint is bioequivalence. Taste, disintegration, and dissolution improvements must remain compatible with the reference product’s pharmacokinetic profile. A materially different formulation may require a 505(b)(2) strategy rather than an ordinary ANDA, particularly if it changes administration instructions, dosing flexibility, or absorption.

What excipients are used in ABILIFY oral solution?

Abilify oral solution contains edetate disodium, fructose, glycerin, lactic acid, methylparaben, propylene glycol, purified water, and sodium hydroxide.[3]

What is the commercial role of the liquid excipient system?

The solution uses a cosolvent and sweetness platform to maintain aripiprazole in a usable liquid presentation. The principal functions are:

Excipient	Function
Propylene glycol	Cosolvent
Glycerin	Cosolvent, humectant, mouthfeel modifier
Fructose	Sweetener
Lactic acid	pH adjustment
Sodium hydroxide	pH adjustment
Edetate disodium	Chelating agent
Methylparaben	Preservative
Purified water	Vehicle

Liquid aripiprazole has commercial value in patients who cannot swallow tablets, including pediatric patients and some institutional-care populations. The most important development risks are chemical stability, precipitation after dilution, preservative effectiveness, container compatibility, dosing-device accuracy, and excipient tolerability.

Potential lifecycle products include:

• preservative-free unit-dose liquids;
• ready-to-use oral syringes;
• lower-sugar formulations;
• ethanol-free or reduced-cosolvent formulations;
• pediatric liquids with improved taste;
• dose-measuring devices with lower administration error;
• stable concentrated solutions requiring smaller administration volumes.

A reformulated liquid with a materially different excipient system may qualify for 505(b)(2) development if it offers a clinical or administration advantage over the listed drug.

Which excipients are used in ABILIFY Maintena and Asimtufii injections?

Abilify Maintena is an extended-release intramuscular suspension containing aripiprazole monohydrate. Its inactive ingredients include carboxymethylcellulose sodium, mannitol, sodium phosphate monobasic monohydrate, sodium hydroxide, and water for injection.[4]

Abilify Asimtufii uses the same general depot excipient architecture, with a longer dosing interval supported by its formulation and clinical development program.[5]

Excipient	Depot-system role
Aripiprazole monohydrate	Poorly soluble depot particles
Carboxymethylcellulose sodium	Suspending and viscosity-modifying agent
Mannitol	Bulking and tonicity adjustment
Sodium phosphate monobasic monohydrate	Buffering
Sodium hydroxide	pH adjustment
Water for injection	Sterile vehicle

The injectable opportunity is more technically demanding than the oral opportunity. Developers must control particle size distribution, crystal form, sedimentation, redispersibility, syringeability, needle force, reconstitution time, injection volume, local tolerability, and release duration.

What excipient strategies can improve long-acting aripiprazole products?

The most commercially valuable excipient strategies target depot performance rather than simple cost reduction.

Particle engineering

Aripiprazole monohydrate particle size and morphology influence surface area, dissolution, sedimentation, and injection behavior. Controlled crystallization, milling, spray drying, or wet-media processing can alter release while preserving the active form.

Suspending-agent optimization

Carboxymethylcellulose sodium controls suspension viscosity and particle mobility. A higher-viscosity system may reduce sedimentation but increase injection force. A lower-viscosity system may improve administration while creating dose-uniformity risks.

Reconstitution optimization

For lyophilized or powder-based presentations, excipients influence cake structure, reconstitution time, foaming, and dose recovery. A commercial product that reduces preparation steps can gain value in outpatient clinics and specialty pharmacies.

Device-excipient integration

The commercial product is the drug, suspension, diluent, needle, and administration procedure together. Dual-chamber syringes, prefilled systems, smaller-gauge needles, and ready-to-administer presentations can support differentiation even where the excipient composition is not new.

Local tolerability

Excipient concentration, osmolality, pH, viscosity, and injection volume affect pain, induration, and injection-site reactions. Small formulation changes can have commercial consequences if they improve administration acceptance or reduce clinic burden.

What patents protect ABILIFY and its excipient strategy?

The original aripiprazole composition-of-matter patent, U.S. Patent No. 5,006,528, expired in 2015 after patent-term adjustments and pediatric exclusivity considerations.[6] That expiration enabled broad generic entry for immediate-release oral aripiprazole.

Patent protection for later products is more dependent on:

• aripiprazole monohydrate;
• particle size and crystal form;
• injectable depot suspensions;
• dosing intervals;
• reconstitution systems;
• injection devices;
• manufacturing processes;
• treatment methods;
• formulation-specific release profiles.

The commercial distinction is material. An oral aripiprazole generic generally faces a mature ANDA market. A competing long-acting injectable may face formulation, process, device, and method-of-use patents even if the basic active-ingredient patent has expired.

What patent risks apply to an aripiprazole excipient product?

A new excipient combination can encounter several layers of patent risk:

Risk area	Typical issue
Composition	Claims covering a defined excipient ratio or concentration
Physical properties	Particle size, polymorph, crystallinity, viscosity, or dissolution
Manufacturing	Milling, crystallization, sterile processing, or lyophilization
Administration	Injection interval, needle, syringe, or reconstitution method
Clinical use	Maintenance treatment, adherence, or patient-selection claims
Regulatory listing	Orange Book-listed patents for approved drug products

A formulation developer should distinguish a patentable excipient combination from a non-infringing manufacturing improvement. A product may avoid composition claims but still face process or method-of-use exposure.

What is the FDA and Orange Book status of ABILIFY?

The FDA approved Abilify tablets under NDA 021436 in 2002, Abilify Discmelt under NDA 021713 in 2003, and the oral solution under NDA 021436-related labeling and approval history.[1-3] Abilify Maintena was approved in 2013, and Asimtufii was approved in 2023.[4-5]

Immediate-release oral aripiprazole is subject to generic competition through ANDA approvals. FDA-approved generic products include tablet and orally disintegrating tablet presentations from multiple manufacturers. The original oral franchise no longer has meaningful small-molecule exclusivity protection.

Maintena and Asimtufii occupy a different regulatory position. Generic or follow-on injectable competition must demonstrate more than active-ingredient equivalence. Product developers must address suspension properties, release characteristics, injection performance, manufacturing controls, and clinical or pharmacokinetic comparability.

There is no biosimilar pathway for aripiprazole because it is a chemically synthesized small molecule. The relevant competitive pathways are ANDA, 505(b)(2), and potentially a new drug application for a substantially differentiated long-acting product.

When does ABILIFY lose exclusivity, and what generic entry scenarios matter?

The original aripiprazole patent protection ended in 2015, creating broad oral generic entry.[6] The commercial entry scenarios now differ by dosage form.

Product category	Entry profile	Main barrier
Immediate-release tablets	Mature generic market	Price, supply reliability, bioequivalence
ODT	Generic and differentiated formulation competition	Taste masking and rapid disintegration
Oral solution	More limited competition	Stability, taste, preservative system, dosing device
Monthly injectable	Limited complex-product competition	Depot technology and clinical comparability
Two-month injectable	Higher formulation and market-entry barriers	Release duration, device, patent, and clinical package

A generic tablet manufacturer competes primarily on cost and supply. A long-acting injectable competitor competes on manufacturing capability, regulatory evidence, contracting, distribution, and clinical adoption.

Which companies are challenging the ABILIFY franchise?

The oral aripiprazole market includes generic manufacturers such as Teva, Sandoz, Alembic, Aurobindo, Dr. Reddy’s, Hikma, and other ANDA holders, depending on product strength and presentation.[7] Market participation changes over time as approvals, launches, supply contracts, and discontinuations change.

The long-acting injectable market has had fewer direct competitors than oral aripiprazole. Potential entrants face complex-product development and commercial barriers that do not apply to tablets. A successful entrant would need to match dosing convenience, injection logistics, stability, release duration, and payer positioning.

How strong is the ABILIFY excipient and formulation patent estate?

The estate is strongest around long-acting injectable delivery and weakest around conventional oral tablets.

Segment	Relative patent strength	Commercial assessment
Original tablet excipients	Low	Standard excipients are difficult to protect broadly
ODT taste masking	Moderate	Protection depends on specific resin, coating, and process claims
Oral solution	Moderate	Stability, preservative, and device claims may support differentiation
Monthly depot injection	Stronger	Product, process, particle, and administration claims can overlap
Two-month depot injection	Stronger	Longer-interval release and delivery claims raise entry complexity

Excipient patents are rarely sufficient by themselves to protect a large product. The most durable estates combine excipient composition, physical attributes, manufacturing process, dosage regimen, and device claims.

What licensing and partnership opportunities exist for aripiprazole excipients?

The most practical licensing opportunities are technology transactions rather than licenses to generic excipients. Relevant assets include:

• taste-masking platforms for bitter antipsychotics;
• ion-exchange resin complexes;
• spray-dried dispersions for poorly soluble drugs;
• co-processed ODT excipients;
• sterile suspension platforms;
• controlled-crystallization technology;
• prefilled depot injection systems;
• dual-chamber reconstitution devices;
• pediatric dosing and packaging systems.

A licensing target should provide a measurable advantage in dissolution, stability, injection performance, manufacturing yield, or regulatory differentiation. A standard mannitol, cellulose, povidone, or magnesium stearate supply agreement is usually a procurement matter rather than a defensible pharmaceutical partnership.

What revenue exposure makes ABILIFY formulation opportunities attractive?

The oral franchise has high unit volume but intense price erosion. Long-acting injectables generally produce higher revenue per treated patient and are less exposed to immediate tablet commoditization. Their value comes from adherence, reduced dosing frequency, clinic administration, and payer economics.

Commercial priorities should therefore be ranked as follows:

1. Two-month or longer-interval depot systems.
2. Monthly depot products with easier administration.
3. Pediatric and geriatric oral liquids.
4. Differentiated ODTs with superior taste and packaging.
5. Low-cost immediate-release tablets.

For excipient suppliers, the injectable opportunity can carry greater technical value per customer because sterile manufacturing, process validation, and regulatory support create switching costs. For generic pharmaceutical companies, oral aripiprazole is more accessible but offers thinner margins.

What generic launch risks exist for ABILIFY?

The main risks are:

• accelerated oral price erosion;
• limited differentiation among tablet products;
• inability to establish superior ODT taste or disintegration;
• precipitation or instability in oral liquids;
• depot sedimentation and dose-uniformity failures;
• injection-site tolerability problems;
• patent disputes involving long-acting formulations;
• inadequate manufacturing scale for sterile products;
• payer preference for the incumbent injectable;
• clinic resistance to new preparation or administration procedures.

A generic or 505(b)(2) developer should treat the excipient system as part of the regulatory and commercial package. A technically equivalent formulation that increases injection force, preparation time, or administration volume may be commercially inferior.

What formulations are commercially protected or differentiated?

The strongest differentiation opportunities are formulations that change patient or provider economics:

• a ready-to-administer long-acting suspension;
• a two-month or longer-interval injectable;
• an ODT with superior taste and low friability;
• a pediatric liquid with low administration volume;
• a prefilled oral syringe;
• a depot product with reduced injection pain;
• a stable formulation with less stringent handling requirements.

A simple substitution of one conventional filler or lubricant for another is unlikely to produce durable commercial protection. The highest-value excipient strategy links composition to a measurable performance claim and, where possible, a patentable physical or manufacturing parameter.

Key Takeaways

• ABILIFY is aripiprazole, a small-molecule antipsychotic with mature oral generic competition.
• The original composition-of-matter patent expired in 2015, so tablet value is driven by manufacturing cost, supply, and limited formulation differentiation.
• ODT opportunities center on taste masking, rapid disintegration, tablet robustness, and packaging.
• Oral-solution opportunities center on solubility management, preservative systems, taste, stability, and dosing accuracy.
• Maintena and Asimtufii offer the strongest commercial opportunities because depot formulations create higher technical and regulatory barriers.
• Aripiprazole has no biosimilar pathway. Relevant pathways are ANDA, 505(b)(2), and new drug applications.
• The strongest patent strategies combine excipient composition with particle properties, manufacturing methods, devices, and dosing regimens.
• Licensing value is highest for depot suspension technology, taste masking, sterile delivery systems, and pediatric administration platforms.

FAQs about ABILIFY excipient and formulation opportunities

Can a generic manufacturer change the excipients in ABILIFY tablets?

Yes. An ANDA may use different inactive ingredients if the product meets applicable sameness, safety, bioequivalence, quality, and labeling requirements. The change cannot materially alter performance without supporting regulatory evidence.

Is aripiprazole suitable for an amorphous solid dispersion?

Potentially. Aripiprazole’s low water solubility makes it a candidate for particle engineering, polymeric dispersion, or other solubility-enhancement approaches. The commercial value depends on achieving improved dissolution without changing exposure or stability.

Which excipient is most important in ABILIFY Maintena?

Carboxymethylcellulose sodium is central to suspension behavior because it affects viscosity, sedimentation, redispersibility, and injection force. Particle engineering and aripiprazole monohydrate properties are equally important to release duration.

Does ABILIFY have biosimilar competition?

No. Aripiprazole is a chemically synthesized small molecule. Competitors use generic-drug, hybrid, or new-drug regulatory pathways rather than the biosimilar pathway.

What is the best commercial entry point for a new ABILIFY formulation?

A differentiated long-acting injectable or a pediatric oral product generally offers more defensible value than another conventional tablet. The strongest candidates reduce dosing frequency, simplify administration, improve tolerability, or solve a clear adherence problem.

References

1. U.S. Food and Drug Administration. (2023). Abilify (aripiprazole) tablets: Prescribing information. Otsuka Pharmaceutical Co., Ltd.

2. U.S. Food and Drug Administration. (2023). Abilify Discmelt (aripiprazole) orally disintegrating tablets: Prescribing information. Otsuka Pharmaceutical Co., Ltd.

3. U.S. Food and Drug Administration. (2023). Aripiprazole oral solution: Prescribing information. Otsuka Pharmaceutical Co., Ltd.

4. U.S. Food and Drug Administration. (2023). Abilify Maintena (aripiprazole) extended-release injectable suspension: Prescribing information. Otsuka Pharmaceutical Co., Ltd.

5. U.S. Food and Drug Administration. (2023). Abilify Asimtufii (aripiprazole) extended-release injectable suspension: Prescribing information. Otsuka Pharmaceutical Co., Ltd.

6. U.S. Patent No. 5,006,528. (1991). Carbostyril derivatives. United States Patent and Trademark Office.

7. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs and generic aripiprazole products. FDA.